BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, there is no expected impact to the timing of 15-day FDA approval or to the company’s manufacturing capacity and its 2025 revenue guidance was reiterated, the analyst tells investors in a research note. The firm believes the warning letter is “unfortunate but not thesis changing.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Resilience Amid FDA Warning: Buy Rating Affirmed by Analyst
- DexCom falls 7% to $71.99 after receiving warning letter from FDA
- DexCom receives warning letter from FDA, sees no impact to FY25 guidance
- Dexcom’s Strong Market Position and Growth Potential Drive Buy Rating and Price Target Increase
- DexCom price target raised to $104 from $101 at Citi